Abstract
Bullous pemphigoid is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. This disease typically affects the elderly and presents with itch and localized or generalized bullous lesions. In up to 20% of affected patients blister may be completely absent, and only excoriations, prurigo-like lesions, eczematous lesions, urticated lesions, and/or infiltrated plaques are observed. The disease is significantly associated with neurological disorders. The morbidity of bullous pemphigoid and its impact on the quality of life are significant. So far, a limited number of national treatment guidelines have been proposed, but no common European consensus has emerged. This guideline for the treatment of bullous pemphigoid has been developed by an Italian group of experts taking in account the Italian legislation and local pharmacological governance. Guidelines are adapted from the original article under the guidance of the European Dermatology Forum (EDF) in collaboration with the European Academy of Dermatology and Venereology (EADV). It summarizes evidence-based and expert-based recommendations (S2 level).
| Original language | English |
|---|---|
| Pages (from-to) | 305-315 |
| Number of pages | 11 |
| Journal | Giornale Italiano di Dermatologia e Venereologia |
| Volume | 153 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Jun 1 2018 |
Fingerprint
Keywords
- Bullous pemphigoid
- Guideline
- Quality of life
- Rare diseases
ASJC Scopus subject areas
- Dermatology
Cite this
Bullous pemphigoid : Italian guidelines adapted from the EDF/EADV guidelines. / Cutaneous Immunology group of SIDeMaST.
In: Giornale Italiano di Dermatologia e Venereologia, Vol. 153, No. 3, 01.06.2018, p. 305-315.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Bullous pemphigoid
T2 - Italian guidelines adapted from the EDF/EADV guidelines
AU - Cutaneous Immunology group of SIDeMaST
AU - Cozzani, Emanuele
AU - Marzano, Angelo V.
AU - Caproni, Marzia
AU - Feliciani, Claudio
AU - Calzavara-Pinton, Piergiacomo
AU - Alaibac, Mauro
AU - Antiga, Emiliano
AU - Arisi, Mariachiara
AU - Assalve, Danilo
AU - Atzori, Laura
AU - Babino, Graziella
AU - Balato, Anna
AU - Balato, Nicola
AU - Barbagallo, Tania
AU - Fortina, Anna Belloni
AU - Berardesca, Enzo
AU - Berti, Emilio
AU - Borghi, Alessandro
AU - Brazzelli, Valeria
AU - Brumana, Marta B.
AU - Brusati, Carlo
AU - Caccavale, Stefano
AU - Caldarola, Giacomo
AU - Campanati, Anna
AU - Caro, Raffaele D.Caposiena
AU - Coati, Ilaria
AU - Conti, Andrea
AU - Costanzo, Antonio
AU - Dattola, Annunziata
AU - De Simone, Clara
AU - Di Cesare, Antonella
AU - Di Lernia, Vito
AU - Di Zenzo, Giovanni M.
AU - Fania, Luca
AU - Filosa, Giorgio
AU - Filotico, Raffaele
AU - Fusano, Marta
AU - Galluccio, Antonia Gerarda
AU - Ganzetti, Giulia
AU - Gisondi, Paolo
AU - Guarneri, Fabrizio
AU - Hansel, Katharina
AU - Javor, Sanja
AU - Laplaca, Michelangelo
AU - Liberati, Giulia
AU - Lora, Viviana
AU - Parodi, Aurora
AU - Patrizi, Annalisa
AU - Tavecchio, Simona
AU - Vassallo, Camilla
PY - 2018/6/1
Y1 - 2018/6/1
N2 - Bullous pemphigoid is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. This disease typically affects the elderly and presents with itch and localized or generalized bullous lesions. In up to 20% of affected patients blister may be completely absent, and only excoriations, prurigo-like lesions, eczematous lesions, urticated lesions, and/or infiltrated plaques are observed. The disease is significantly associated with neurological disorders. The morbidity of bullous pemphigoid and its impact on the quality of life are significant. So far, a limited number of national treatment guidelines have been proposed, but no common European consensus has emerged. This guideline for the treatment of bullous pemphigoid has been developed by an Italian group of experts taking in account the Italian legislation and local pharmacological governance. Guidelines are adapted from the original article under the guidance of the European Dermatology Forum (EDF) in collaboration with the European Academy of Dermatology and Venereology (EADV). It summarizes evidence-based and expert-based recommendations (S2 level).
AB - Bullous pemphigoid is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. This disease typically affects the elderly and presents with itch and localized or generalized bullous lesions. In up to 20% of affected patients blister may be completely absent, and only excoriations, prurigo-like lesions, eczematous lesions, urticated lesions, and/or infiltrated plaques are observed. The disease is significantly associated with neurological disorders. The morbidity of bullous pemphigoid and its impact on the quality of life are significant. So far, a limited number of national treatment guidelines have been proposed, but no common European consensus has emerged. This guideline for the treatment of bullous pemphigoid has been developed by an Italian group of experts taking in account the Italian legislation and local pharmacological governance. Guidelines are adapted from the original article under the guidance of the European Dermatology Forum (EDF) in collaboration with the European Academy of Dermatology and Venereology (EADV). It summarizes evidence-based and expert-based recommendations (S2 level).
KW - Bullous pemphigoid
KW - Guideline
KW - Quality of life
KW - Rare diseases
UR - http://www.scopus.com/inward/record.url?scp=85047295577&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047295577&partnerID=8YFLogxK
U2 - 10.23736/S0392-0488.18.06006-6
DO - 10.23736/S0392-0488.18.06006-6
M3 - Review article
AN - SCOPUS:85047295577
VL - 153
SP - 305
EP - 315
JO - Minerva dermatologica
JF - Minerva dermatologica
SN - 0392-0488
IS - 3
ER -